Cochrane · systematic review · CD012906
Metformin monotherapy for adults with type 2 diabetes mellitus
Gnesin, F, Thuesen, AC, Kähler, LK, et al. · Cochrane Database of Systematic Reviews · 2020 · Cochrane Library
Metabolic and Endocrine DisordersAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
42
current version
GRADE rated
21
No studies
20
Included studies
NR
No studies 20 · 47.6%Ungraded 1 · 2.4%Very low 21 · 50%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Summary of findings of metformin monotherapy for adults with type 2 diabetes mellitus: metformin versus insulin
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality Summary of findings of metformin monotherapy for adults with type 2 diabetes mellitus: metformin vs insulin | no estimate extracted | NR | No studies |
Serious adverse events Summary of findings of metformin monotherapy for adults with type 2 diabetes mellitus: metformin vs insulin | no estimate extracted | NR | No studies |
Health‐related quality of life (Short Form‐36 version 2 questionnaire) Summary of findings of metformin monotherapy for adults with type 2 diabetes mellitus: metformin vs insulin | no estimate extracted | 1 study · 91 participants | Very low Downgraded: risk of bias, imprecision |
Cardiovascular mortality Summary of findings of metformin monotherapy for adults with type 2 diabetes mellitus: metformin vs insulin | no estimate extracted | NR | No studies |
Non‐fatal myocardial infarction Summary of findings of metformin monotherapy for adults with type 2 diabetes mellitus: metformin vs insulin | no estimate extracted | NR | No studies |
Non‐fatal stroke Summary of findings of metformin monotherapy for adults with type 2 diabetes mellitus: metformin vs insulin | no estimate extracted | NR | No studies |
End‐stage renal disease Summary of findings of metformin monotherapy for adults with type 2 diabetes mellitus: metformin vs insulin | no estimate extracted | NR | No studies |
Summary of findings of metformin monotherapy for adults with type 2 diabetes mellitus: metformin versus sulphonylureas
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality Summary of findings of metformin monotherapy for adults with type 2 diabetes mellitus: metformin vs sulphonylureas | no estimate extracted | 4 studies · 3129 participants | Very low Downgraded: risk of bias, imprecision |
Serious adverse events (SAE) Summary of findings of metformin monotherapy for adults with type 2 diabetes mellitus: metformin vs sulphonylureas | no estimate extracted | 3 studies · 3081 participants | Very low Downgraded: risk of bias, imprecision |
Health‐related quality of life Summary of findings of metformin monotherapy for adults with type 2 diabetes mellitus: metformin vs sulphonylureas | no estimate extracted | NR | No studies |
Cardiovascular mortality (CVM) Summary of findings of metformin monotherapy for adults with type 2 diabetes mellitus: metformin vs sulphonylureas | no estimate extracted | 2 studies · 2940 participants | Very low Downgraded: risk of bias, imprecision |
Non‐fatal myocardial infarction (NFMI) Summary of findings of metformin monotherapy for adults with type 2 diabetes mellitus: metformin vs sulphonylureas | no estimate extracted | 3 studies · 3047 participants | Very low Downgraded: risk of bias, imprecision |
Non‐fatal stroke (NFS) Summary of findings of metformin monotherapy for adults with type 2 diabetes mellitus: metformin vs sulphonylureas | no estimate extracted | 1 study · 72 participants | Very low Downgraded: risk of bias, imprecision |
End‐stage renal disease Summary of findings of metformin monotherapy for adults with type 2 diabetes mellitus: metformin vs sulphonylureas | no estimate extracted | NR | No studies |
Summary of findings of metformin monotherapy for adults with type 2 diabetes mellitus: metformin versus thiazolidinediones
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality Summary of findings of metformin monotherapy for adults with type 2 diabetes mellitus: metformin vs thiazolidinediones | RR 0.88 [0.55, 1.39] | 5 studies · 4402 participants | Very low Downgraded: risk of bias, imprecision |
Serious adverse events (SAE) Summary of findings of metformin monotherapy for adults with type 2 diabetes mellitus: metformin vs thiazolidinediones | RR 0.95 [0.84, 1.09] | 4 studies · 3208 participants | Very low Downgraded: risk of bias, imprecision |
Health‐related quality of life Summary of findings of metformin monotherapy for adults with type 2 diabetes mellitus: metformin vs thiazolidinediones | no estimate extracted | NR | No studies |
Cardiovascular mortality (CVM) Summary of findings of metformin monotherapy for adults with type 2 diabetes mellitus: metformin vs thiazolidinediones | RR 0.71 [0.21, 2.39] | 4 studies · 3211 participants | Very low Downgraded: risk of bias, imprecision |
Non‐fatal myocardial infarction (NFMI) Summary of findings of metformin monotherapy for adults with type 2 diabetes mellitus: metformin vs thiazolidinediones | no estimate extracted | 3 studies · 3020 participants | Very low Downgraded: risk of bias, imprecision |
Non‐fatal stroke (NFS) Summary of findings of metformin monotherapy for adults with type 2 diabetes mellitus: metformin vs thiazolidinediones | no estimate extracted | 1 study · 72 participants | Very low Downgraded: risk of bias, imprecision |
End‐stage renal disease Summary of findings of metformin monotherapy for adults with type 2 diabetes mellitus: metformin vs thiazolidinediones | no estimate extracted | NR | No studies |
Summary of findings of metformin monotherapy for adults with type 2 diabetes mellitus: metformin versus dipeptidyl‐peptidase 4 inhibitors
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality Summary of findings of metformin monotherapy for adults with type 2 diabetes mellitus: metformin vs dipeptidyl‐peptidase 4 inhibitors | no estimate extracted | 3 studies · 1977 participants | Very low Downgraded: risk of bias, imprecision |
Serious adverse events (SAE) Summary of findings of metformin monotherapy for adults with type 2 diabetes mellitus: metformin vs dipeptidyl‐peptidase 4 inhibitors | no estimate extracted | 3 studies · 1977 participants | Very low Downgraded: risk of bias, imprecision |
Health‐related quality of life Summary of findings of metformin monotherapy for adults with type 2 diabetes mellitus: metformin vs dipeptidyl‐peptidase 4 inhibitors | no estimate extracted | NR | No studies |
Cardiovascular mortality (CVM) Summary of findings of metformin monotherapy for adults with type 2 diabetes mellitus: metformin vs dipeptidyl‐peptidase 4 inhibitors | no estimate extracted | 2 studies · 1206 participants | Very low Downgraded: risk of bias, imprecision |
Non‐fatal myocardial infarction (NFMI) Summary of findings of metformin monotherapy for adults with type 2 diabetes mellitus: metformin vs dipeptidyl‐peptidase 4 inhibitors | no estimate extracted | 1 study · 543 participants | Very low Downgraded: risk of bias, imprecision |
Non‐fatal stroke (NFS) Summary of findings of metformin monotherapy for adults with type 2 diabetes mellitus: metformin vs dipeptidyl‐peptidase 4 inhibitors | no estimate extracted | 1 study · 543 participants | Very low Downgraded: risk of bias, imprecision |
End‐stage renal disease Summary of findings of metformin monotherapy for adults with type 2 diabetes mellitus: metformin vs dipeptidyl‐peptidase 4 inhibitors | no estimate extracted | NR | No studies |
Summary of findings of metformin monotherapy for adults with type 2 diabetes mellitus: metformin versus glucagon like peptide‐1 analogues
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality Summary of findings of metformin monotherapy for adults with type 2 diabetes mellitus: metformin vs glucagon like peptide‐1 analogues | no estimate extracted | 1 study · 807 participants | Very low Downgraded: risk of bias, imprecision |
Serious adverse events (SAE) Summary of findings of metformin monotherapy for adults with type 2 diabetes mellitus: metformin vs glucagon like peptide‐1 analogues | no estimate extracted | 1 study · 807 participants | Very low Downgraded: risk of bias, imprecision |
Health‐related quality of life Summary of findings of metformin monotherapy for adults with type 2 diabetes mellitus: metformin vs glucagon like peptide‐1 analogues | no estimate extracted | NR | No studies |
Cardiovascular mortality (CVM) Summary of findings of metformin monotherapy for adults with type 2 diabetes mellitus: metformin vs glucagon like peptide‐1 analogues | no estimate extracted | 1 study · 807 participants | Very low Downgraded: risk of bias, imprecision |
Non‐fatal myocardial infarction (NFMI) Summary of findings of metformin monotherapy for adults with type 2 diabetes mellitus: metformin vs glucagon like peptide‐1 analogues | no estimate extracted | 1 study · 807 participants | Very low Downgraded: risk of bias, imprecision |
Non‐fatal stroke (NFS) Summary of findings of metformin monotherapy for adults with type 2 diabetes mellitus: metformin vs glucagon like peptide‐1 analogues | no estimate extracted | 1 study · 807 participants | Very low Downgraded: risk of bias, imprecision |
End‐stage renal disease Summary of findings of metformin monotherapy for adults with type 2 diabetes mellitus: metformin vs glucagon like peptide‐1 analogues | no estimate extracted | NR | No studies |
Summary of findings of metformin monotherapy for adults with type 2 diabetes mellitus: metformin versus meglitinides
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality Summary of findings of metformin monotherapy for adults with type 2 diabetes mellitus: metformin vs meglitinides | no estimate extracted | NR | No studies |
Serious adverse events Summary of findings of metformin monotherapy for adults with type 2 diabetes mellitus: metformin vs meglitinides | no estimate extracted | 1 study · 112 participants | Ungraded |
Health‐related quality of life Summary of findings of metformin monotherapy for adults with type 2 diabetes mellitus: metformin vs meglitinides | no estimate extracted | NR | No studies |
Cardiovascular mortality Summary of findings of metformin monotherapy for adults with type 2 diabetes mellitus: metformin vs meglitinides | no estimate extracted | NR | No studies |
Non‐fatal myocardial infarction Summary of findings of metformin monotherapy for adults with type 2 diabetes mellitus: metformin vs meglitinides | no estimate extracted | NR | No studies |
Non‐fatal stroke Summary of findings of metformin monotherapy for adults with type 2 diabetes mellitus: metformin vs meglitinides | no estimate extracted | NR | No studies |
End‐stage renal disease Summary of findings of metformin monotherapy for adults with type 2 diabetes mellitus: metformin vs meglitinides | no estimate extracted | NR | No studies |